• Explore /
  • Poster
  • / Exploratory analysis of the effect of taselisib on downstream pathway modulation and correlation with tumor response in ER-positive/HER2-negative early-stage breast cancer from the LORELEI trial.

Exploratory analysis of the effect of taselisib on downstream pathway modulation and correlation with tumor response in ER-positive/HER2-negative early-stage breast cancer from the LORELEI trial.

Abstract Poster

Authors

null

Paolo Nuciforo

Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

Paolo Nuciforo , Dominik Hlauschek , Cristina Saura , Evandro de Azambuja , Roberta Fasani , Patricia Villagrasa , Karoline Muehlbacher , Christos Sotiriou , Aleix Prat , Georg Pfeiler , Florentine Hilbers , Timothy R. Wilson , Junko Aimi , Thomas Stout , Vicente Valero , Christian Fesl , Jose Baselga , Michael Gnant , Martine Piccart , Fabrice Andre

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Hormone Receptor-Positive

Clinical Trial Registration Number

NCT02273973

Citation

J Clin Oncol 37, 2019 (suppl; abstr 1050)

DOI

10.1200/JCO.2019.37.15_suppl.1050

Abstract #

1050

Poster Bd #

131

Abstract Disclosures

Similar Posters

First Author: Cristina Saura

First Author: Javier Pascual

First Author: Sarah-Jane Dawson

First Author: Otto Metzger Filho